IL6 and injury: A recent Phase 2 clinical trial titled “Ganciclovir/Valganciclovir for the Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure (GRAIL)” (NCT01335932) was conducted to determine whether administration of prophylactic antiviral treatment for CMV reduces plasma interleukin 6 (IL-6) level in immunocompetent adults with severe sepsis or trauma-associated respiratory failure.